{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:30:26Z","timestamp":1786350626302,"version":"build-2736575974"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a global epidemic of obesity and in this context, the development of novel agents for weight loss has been timely. There have been emerging reports of peripheral nerve complications and this study aimed to systematically review all reported cases associated with medications used for weight loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Embase and CINAHL databases from inception to 30 June 2026 was performed to identify studies that report new-onset or worsening peripheral nerve complications. Independent screening was conducted by two authors. Data including demographics, medications, weight-loss parameters, neurological presentation and investigations. Descriptive statistics were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 19 studies, comprising 31 cases and one cohort (103 individuals) identified. All bar one were published from 2024. Of 31 individual cases median weight loss achieved was 20.4 kg (IQR 15.2) or 21.8% (IQR 16.4) of starting body weight. Median rate of weight loss was 3.7 kg\/month (IQR 1.7), with symptom onset at 150 days (IQR 135). Semaglutide or tirzepatide were implicated in the majority (83%), and 67% had pre-diabetes\/diabetes. Neurological presentations included fibular neuropathy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910), lumbosacral radiculoplexus neuropathy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099) and distal symmetric polyneuropathy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097). Electrodiagnostic and imaging data were supportive of diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is a recent increase in peripheral nerve disorders associated with medical treatment of diabetes and obesity. To reduce the risk, it is recommended to ensure adequate nutritional status and avoid ultrarapid HbA1c and weight loss. Prospective studies are needed to determine incidence and confirm safe rates of weight loss and glycemic correction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-14048-w","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:14:49Z","timestamp":1785777289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral nerve complications from medications utilised for weight loss: a systematic review"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5262-9597","authenticated-orcid":false,"given":"Cullen","family":"O\u2019Gorman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"10481","key":"14048_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"M Ng","year":"2025","unstructured":"Ng M et al (2025) Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 405(10481):813\u2013838","journal-title":"Lancet"},{"issue":"10370","key":"14048_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0140-6736(22)02576-4","volume":"401","author":"N Kanem","year":"2023","unstructured":"Kanem N, Murray CJ, Horton R (2023) The lancet commission on 21st-century global health threats. Lancet 401(10370):10\u201311","journal-title":"Lancet"},{"key":"14048_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009773","author":"A Okunogbe","year":"2022","unstructured":"Okunogbe A et al (2022) Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. https:\/\/doi.org\/10.1136\/bmjgh-2022-009773","journal-title":"BMJ Glob Health"},{"issue":"1","key":"14048_CR4","volume":"1","author":"CE Naude","year":"2022","unstructured":"Naude CE et al (2022) Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk. Cochrane Database Syst Rev 1(1):Cd013334","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"14048_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1037\/amp0000517","volume":"75","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Butryn ML (2020) Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol 75(2):235\u2013251","journal-title":"Am Psychol"},{"issue":"9","key":"14048_CR6","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","volume":"115","author":"MJ Franz","year":"2015","unstructured":"Franz MJ et al (2015) Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet 115(9):1447\u20131463","journal-title":"J Acad Nutr Diet"},{"issue":"3","key":"14048_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamasurg.2013.3654","volume":"149","author":"S-H Chang","year":"2014","unstructured":"Chang S-H et al (2014) The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003\u20132012. JAMA Surg 149(3):275\u2013287","journal-title":"JAMA Surg"},{"key":"14048_CR8","doi-asserted-by":"crossref","unstructured":"Vilsb\u00f8ll T et al (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Bmj, 344","DOI":"10.1136\/bmj.d7771"},{"issue":"2","key":"14048_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","volume":"48","author":"HJ Wong","year":"2025","unstructured":"Wong HJ et al (2025) Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care 48(2):292\u2013300","journal-title":"Diabetes Care"},{"issue":"3","key":"14048_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s12325-022-02394-w","volume":"40","author":"PW Moore","year":"2023","unstructured":"Moore PW et al (2023) GLP-1 agonists for weight loss: pharmacology and clinical implications. Adv Ther 40(3):723\u2013742","journal-title":"Adv Ther"},{"key":"14048_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.peptides.2017.12.009","volume":"100","author":"E Brown","year":"2018","unstructured":"Brown E, Cuthbertson DJ, Wilding JP (2018) Newer GLP-1 receptor agonists and obesity-diabetes. Peptides 100:61\u201367","journal-title":"Peptides"},{"key":"14048_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1095753","volume":"14","author":"I Zaffina","year":"2023","unstructured":"Zaffina I et al (2023) Effect of dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. Front Endocrinol (Lausanne) 14:1095753","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"14048_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7249\/rhq-13-01-03","volume":"13","author":"R Bozick","year":"2025","unstructured":"Bozick R, Donofry SD, Ranca\u00f1o KM (2025) New weight loss drugs: GLP-1 agonist use and side effects in the United States. Rand Health Q 13(1):3","journal-title":"Rand Health Q"},{"key":"14048_CR14","first-page":"1","volume":"12","author":"J Paget","year":"1876","unstructured":"Paget J (1876) On some of the sequels of typhoid fever. St. Bartholomew\u2019s Hosp Rep 12:1\u20134","journal-title":"St. Bartholomew\u2019s Hosp Rep"},{"issue":"8","key":"14048_CR15","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1212\/01.WNL.0000142038.43946.06","volume":"63","author":"P Thaisetthawatkul","year":"2004","unstructured":"Thaisetthawatkul P et al (2004) A controlled study of peripheral neuropathy after bariatric surgery. Neurology 63(8):1462\u20131470","journal-title":"Neurology"},{"issue":"2","key":"14048_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1046\/j.1529-8027.2000.00007.x","volume":"5","author":"A Cruz-Martinez","year":"2000","unstructured":"Cruz-Martinez A, Arpa J, Palau F (2000) Peroneal neuropathy after weight loss. J Peripher Nerv Syst 5(2):101\u2013105","journal-title":"J Peripher Nerv Syst"},{"issue":"7","key":"14048_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1445-5994.2012.02836.x","volume":"42","author":"NG Simon","year":"2012","unstructured":"Simon NG, Kiernan MC (2012) Common peroneal neuropathy and cancer. Intern Med J 42(7):837\u2013840","journal-title":"Intern Med J"},{"issue":"2","key":"14048_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1590\/1516-4446-2015-1846","volume":"38","author":"AL Teixeira","year":"2016","unstructured":"Teixeira AL et al (2016) Anorexia nervosa presenting as a subacute sensory-motor axonal polyneuropathy. Braz J Psychiatry 38(2):180","journal-title":"Braz J Psychiatry"},{"issue":"2","key":"14048_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.20394","volume":"33","author":"BM Koffman","year":"2006","unstructured":"Koffman BM et al (2006) Neurologic complications after surgery for obesity. Muscle Nerve 33(2):166\u2013176","journal-title":"Muscle Nerve"},{"issue":"6366","key":"14048_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0140-6736(45)90723-9","volume":"246","author":"JD Spillane","year":"1945","unstructured":"Spillane JD, Scott GI (1945) Obscure neuropathy in the Middle East: report on 112 cases in prisoners-of-war. Lancet 246(6366):261\u2013264","journal-title":"Lancet"},{"issue":"1","key":"14048_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00005792-194702000-00002","volume":"26","author":"D Denny-Brown","year":"1947","unstructured":"Denny-Brown D (1947) Neurological conditions resulting from prolonged and severe dietary restriction. Medicine (Baltimore) 26(1):41\u2013113","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"14048_CR22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jama.1929.02710090010004","volume":"93","author":"HW Woltman","year":"1929","unstructured":"Woltman HW (1929) Crossing the legs as a factor in the production of peroneal palsy. JAMA 93(9):670\u2013672","journal-title":"JAMA"},{"issue":"5","key":"14048_CR23","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/jnnp.47.5.564","volume":"47","author":"KA Sotaniemi","year":"1984","unstructured":"Sotaniemi KA (1984) Slimmer\u2019s paralysis--peroneal neuropathy during weight reduction. J Neurol Neurosurg Psychiatry 47(5):564\u2013566","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"14048_CR24","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s11695-007-9203-2","volume":"17","author":"FJ Weyns","year":"2007","unstructured":"Weyns FJ et al (2007) Foot drop as a complication of weight loss after bariatric surgery: is it preventable? Obes Surg 17(9):1209\u20131212","journal-title":"Obes Surg"},{"issue":"10","key":"14048_CR25","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s11695-014-1376-x","volume":"24","author":"A Landais","year":"2014","unstructured":"Landais A (2014) Neurological complications of bariatric surgery. Obes Surg 24(10):1800\u20131807","journal-title":"Obes Surg"},{"issue":"1","key":"14048_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00415-025-13566-3","volume":"273","author":"C O'Gorman","year":"2025","unstructured":"O\u2019Gorman C (2025) Peripheral nerve complications of weight loss associated with novel antihyperglycemic agents: a cohort study. J Neurol 273(1):33","journal-title":"J Neurol"},{"key":"14048_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-026-04079-7","author":"ML Laroche","year":"2026","unstructured":"Laroche ML, G\u00e9niaux H, Jardou M (2026) Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. Eur J Clin Pharmacol. https:\/\/doi.org\/10.1007\/s00228-026-04079-7","journal-title":"Eur J Clin Pharmacol"},{"issue":"13","key":"14048_CR28","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1093\/ajhp\/zxag077","volume":"83","author":"M Cestari","year":"2026","unstructured":"Cestari M et al (2026) Peripheral neuropathic symptoms with GLP-1 receptor agonists: insights from a large real-world cohort. Am J Health Syst Pharm 83(13):e459\u2013e459","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"14048_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2046-4053-1-2","volume":"1","author":"A Booth","year":"2012","unstructured":"Booth A et al (2012) The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev 1(1):2","journal-title":"Syst Rev"},{"key":"14048_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","author":"MJ Page","year":"2020","unstructured":"Page MJ et al (2020) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n160","journal-title":"BMJ"},{"issue":"3","key":"14048_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","volume":"3","author":"Z Munn","year":"2014","unstructured":"Munn Z et al (2014) The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 3(3):123","journal-title":"Int J Health Policy Manag"},{"issue":"S32","key":"14048_CR32","first-page":"S201","volume":"96","author":"F Ali","year":"2024","unstructured":"Ali F (2024) M2.015 Chicken or the egg: ozempic or type II diabetes related to symptoms of distal polyneuropathy. Ann Neurol 96(S32):S201","journal-title":"Ann Neurol"},{"key":"14048_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2026.125755","volume":"481","author":"S Chandrashekhar","year":"2026","unstructured":"Chandrashekhar S et al (2026) Diabetic lumbosacral radiculoplexus neuropathy after glucagon-like peptide 1 receptor agonist use: a case series. J Neurol Sci 481:125755","journal-title":"J Neurol Sci"},{"issue":"7 Suppl 1","key":"14048_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211255","volume":"104","author":"D Desai","year":"2025","unstructured":"Desai D (2025) Bilateral peroneal neuropathy associated with semaglutide related rapid weight loss: a case report (P10-11.019). Neurology 104(7 Suppl 1):3812","journal-title":"Neurology"},{"issue":"1","key":"14048_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/SAP.0000000000004570","volume":"96","author":"P Dhupati","year":"2026","unstructured":"Dhupati P et al (2026) GLP-1 receptor agonist-associated slimmer\u2019s palsy: implications for the peripheral nerve surgeon. Ann Plast Surg 96(1):69\u201374","journal-title":"Ann Plast Surg"},{"key":"14048_CR36","doi-asserted-by":"crossref","unstructured":"Donigan EC et al. (2025) Severe lumbosacral polyradiculopathy secondary to micronutrient deficiencies in a patient on semaglutide therapy following bariatric surgery. Endocrinol Diabetes Metab Case Rep, 3","DOI":"10.1530\/EDM-25-0072"},{"issue":"1","key":"14048_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-026-04664-4","volume":"26","author":"LS Lesinszki","year":"2026","unstructured":"Lesinszki LS et al (2026) Recurrent bilateral brachial plexus neuritis following rapid semaglutide-induced weight loss: a case report. BMC Neurol 26(1):123","journal-title":"BMC Neurol"},{"issue":"Suppl 1","key":"14048_CR38","first-page":"A104","volume":"9","author":"S Obialo","year":"2025","unstructured":"Obialo S, Jaber R, Sukthanker N (2025) Unexpected consequences: Guillain-Barr\u00e9 syndrome following GLP-1 agonist therapy. J Endocr Soc 9(Suppl 1):A104","journal-title":"J Endocr Soc"},{"issue":"7","key":"14048_CR39","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1212\/WNL.0000000000208965","volume":"104","author":"P Paul","year":"2025","unstructured":"Paul P, Chandrashekhar S (2025) Potential risk of diabetic lumbosacral radiculoplexus neuropathy (DLSRPN) in association with glucagon-like-peptide-1 (GLP1) analog: a case series. Neurology 104(7):2166","journal-title":"Neurology"},{"issue":"8","key":"14048_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurpra.2024.105117","volume":"20","author":"N Pennington","year":"2024","unstructured":"Pennington N (2024) Slimmer\u2019s paralysis: a case study of peroneal neuropathy following rapid weight loss. J Nurse Pract 20(8):105117","journal-title":"J Nurse Pract"},{"issue":"8","key":"14048_CR41","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1212\/WNL.0b013e3182825367","volume":"80","author":"L Phillips","year":"2013","unstructured":"Phillips L, Singer MA (2013) Peripheral neuropathy due to dinitrophenol used for weight loss: something old, something new. Neurology 80(8):773\u2013774","journal-title":"Neurology"},{"issue":"5","key":"14048_CR42","first-page":"664","volume":"35","author":"H Shakeel","year":"2025","unstructured":"Shakeel H, Thomas SG, Khalid E (2025) Tirzepatide related polyneuropathy. Clin Auton Res 35(5):664","journal-title":"Clin Auton Res"},{"issue":"3\u20134","key":"14048_CR43","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/21678421.2024.2446847","volume":"26","author":"K Stolwyk","year":"2025","unstructured":"Stolwyk K, Lee I (2025) Rapid progression of amyotrophic lateral sclerosis after initiation of GLP-1 agonist: a case report. Amyotroph Lateral Scler Frontotemporal Degener 26(3\u20134):382\u2013384","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"14048_CR44","doi-asserted-by":"crossref","unstructured":"Tanyous A, Levitt J (2026) Weight drop - foot drop: two cases a case series of peroneal nerve palsy from leg crossing after tirzepatide-mediated weight loss. Case Rep Neurol","DOI":"10.1159\/000552890"},{"issue":"3","key":"14048_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213916","volume":"105","author":"JD Triplett","year":"2025","unstructured":"Triplett JD et al (2025) GLP-1RA-associated diabetic lumbosacral radiculoplexus and common fibular neuropathies: a case-control evaluation. Neurology 105(3):e213916","journal-title":"Neurology"},{"issue":"3","key":"14048_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/23247096241264635","volume":"12","author":"JM Tucker","year":"2024","unstructured":"Tucker JM, Ritchie J (2024) The tirzepatide drop: beware of slimmer\u2019s paralysis. J Investig Med High Impact Case Rep 12(3):23247096241264635","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"1","key":"14048_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12883-025-04540-7","volume":"26","author":"A Zahir","year":"2025","unstructured":"Zahir A et al (2025) Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report. BMC Neurol 26(1):5","journal-title":"BMC Neurol"},{"issue":"3","key":"14048_CR48","first-page":"233","volume":"10","author":"J Wen","year":"2026","unstructured":"Wen J et al (2026) Brachial plexopathy following rapid weight loss from tirzepatide: a case report. Pain Med Case Rep 10(3):233\u2013236","journal-title":"Pain Med Case Rep"},{"key":"14048_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100115","volume":"11","author":"MJ Sahyouni","year":"2024","unstructured":"Sahyouni MJ et al (2024) Neuropathy of diabetes following initiation of a low-carbohydrate diet: case report. Obes Pillars 11:100115","journal-title":"Obes Pillars"},{"issue":"Suppl 1","key":"14048_CR50","first-page":"S110","volume":"45","author":"L Stabile","year":"2026","unstructured":"Stabile L et al (2026) P116 - A painful lumbosacral radiculoplexopathy in a non-diabetic patient exposed to tirzepatide: expanding the spectrum of GLP-1RA-associated neuropathies. Acta Myol 45(Suppl 1):S110","journal-title":"Acta Myol"},{"issue":"5","key":"14048_CR51","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/WCO.0000000000001292","volume":"37","author":"MA Elafros","year":"2024","unstructured":"Elafros MA, Reynolds EL, Callaghan BC (2024) Obesity-related neuropathy: the new epidemic. Curr Opin Neurol 37(5):467\u2013477","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"14048_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1474-4422(17)30084-4","volume":"16","author":"PD O'Brien","year":"2017","unstructured":"O\u2019Brien PD et al (2017) Neurological consequences of obesity. Lancet Neurol 16(6):465\u2013477","journal-title":"Lancet Neurol"},{"issue":"7","key":"14048_CR53","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.mayocp.2020.03.025","volume":"95","author":"BC Callaghan","year":"2020","unstructured":"Callaghan BC et al (2020) Central obesity is associated with neuropathy in the severely obese. Mayo Clin Proc 95(7):1342\u20131353","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"14048_CR54","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1085-9489.2005.00047.x","volume":"10","author":"G Miscio","year":"2005","unstructured":"Miscio G et al (2005) Obesity and peripheral neuropathy risk: a dangerous liaison. J Peripher Nerv Syst 10(4):354\u2013358","journal-title":"J Peripher Nerv Syst"},{"issue":"9","key":"14048_CR55","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1007\/s12325-022-02208-z","volume":"39","author":"J Lim","year":"2022","unstructured":"Lim J et al (2022) The peripheral neuropathy prevalence and characteristics are comparable in people with obesity and long-duration type 1 diabetes. Adv Ther 39(9):4218\u20134229","journal-title":"Adv Ther"},{"issue":"12","key":"14048_CR56","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1001\/jamaneurol.2016.3745","volume":"73","author":"BC Callaghan","year":"2016","unstructured":"Callaghan BC et al (2016) Association between metabolic syndrome components and polyneuropathy in an obese population. JAMA Neurol 73(12):1468\u20131476","journal-title":"JAMA Neurol"},{"issue":"2","key":"14048_CR57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/sj.ijo.0803418","volume":"31","author":"R Herman","year":"2007","unstructured":"Herman R et al (2007) Prevalence of somatic small fiber neuropathy in obesity. Int J Obes 31(2):226\u2013235","journal-title":"Int J Obes"},{"issue":"19","key":"14048_CR58","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1523\/JNEUROSCI.3173-18.2019","volume":"39","author":"AE Rumora","year":"2019","unstructured":"Rumora AE et al (2019) The divergent roles of dietary saturated and monounsaturated fatty acids on nerve function in murine models of obesity. J Neurosci 39(19):3770\u20133781","journal-title":"J Neurosci"},{"issue":"1","key":"14048_CR59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S0006-8993(02)02910-4","volume":"947","author":"J Ohshima","year":"2002","unstructured":"Ohshima J, Nukada H (2002) Hypoglycaemic neuropathy: microvascular changes due to recurrent hypoglycaemic episodes in rat sciatic nerve. Brain Res 947(1):84\u201389","journal-title":"Brain Res"},{"issue":"6","key":"14048_CR60","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.2337\/dc07-2243","volume":"31","author":"S Dotson","year":"2008","unstructured":"Dotson S et al (2008) Hypoglycemia increases serum interleukin-6 levels in healthy men and women. Diabetes Care 31(6):1222\u20131223","journal-title":"Diabetes Care"},{"issue":"3","key":"14048_CR61","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/BF00418349","volume":"39","author":"S Tesfaye","year":"1996","unstructured":"Tesfaye S et al (1996) Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 39(3):329\u2013335","journal-title":"Diabetologia"},{"issue":"2","key":"14048_CR62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1529-8027.2003.03009.x","volume":"8","author":"H Honma","year":"2003","unstructured":"Honma H et al (2003) Acute glucose deprivation leads to apoptosis in a cell model of acute diabetic neuropathy. J Peripher Nerv Syst 8(2):65\u201374","journal-title":"J Peripher Nerv Syst"},{"issue":"7503","key":"14048_CR63","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nature13475","volume":"510","author":"M Maceyka","year":"2014","unstructured":"Maceyka M, Spiegel S (2014) Sphingolipid metabolites in inflammatory disease. Nature 510(7503):58\u201367","journal-title":"Nature"},{"issue":"2","key":"14048_CR64","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00125-011-2384-1","volume":"55","author":"A Othman","year":"2012","unstructured":"Othman A et al (2012) Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia 55(2):421\u2013431","journal-title":"Diabetologia"},{"issue":"8\u20139","key":"14048_CR65","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.neurol.2011.01.011","volume":"167","author":"N Philippi","year":"2011","unstructured":"Philippi N et al (2011) Peripheral neuropathies after bariatric surgery. Rev Neurol (Paris) 167(8\u20139):607\u2013614","journal-title":"Rev Neurol (Paris)"},{"issue":"5","key":"14048_CR66","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/WCO.0000000000000727","volume":"32","author":"MP Collins","year":"2019","unstructured":"Collins MP, Dyck PJB, Hadden RDM (2019) Update on classification, epidemiology, clinical phenotype and imaging of the nonsystemic vasculitic neuropathies. Curr Opin Neurol 32(5):684\u2013695","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"14048_CR67","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.mayocp.2023.06.011","volume":"99","author":"JB Meiling","year":"2024","unstructured":"Meiling JB et al (2024) Parsonage-Turner syndrome and hereditary brachial plexus neuropathy. Mayo Clin Proc 99(1):124\u2013140","journal-title":"Mayo Clin Proc"},{"issue":"4\u20135","key":"14048_CR68","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/(SICI)1097-0029(19990515\/01)45:4\/5<285::AID-JEMT12>3.0.CO;2-3","volume":"45","author":"L Aloe","year":"1999","unstructured":"Aloe L, Simone MD, Properzi F (1999) Nerve growth factor: a neurotrophin with activity on cells of the immune system. Microsc Res Tech 45(4\u20135):285\u2013291","journal-title":"Microsc Res Tech"},{"issue":"3","key":"14048_CR69","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/EJE-06-0716","volume":"157","author":"M Bull\u00f3","year":"2007","unstructured":"Bull\u00f3 M et al (2007) Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur J Endocrinol 157(3):303\u2013310","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"14048_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165858","volume":"1866","author":"X-W Ding","year":"2020","unstructured":"Ding X-W et al (2020) Nerve growth factor in metabolic complications and Alzheimer\u2019s disease: physiology and therapeutic potential. Mol Basis Dis (BBA: Biochimica et Biophysica Acta) 1866(10):165858","journal-title":"Mol Basis Dis (BBA: Biochimica et Biophysica Acta)"},{"issue":"5","key":"14048_CR71","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00019052-199910000-00014","volume":"12","author":"JD England","year":"1999","unstructured":"England JD (1999) Entrapment neuropathies. Curr Opin Neurol 12(5):597\u2013602","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"14048_CR72","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/obr.12324","volume":"16","author":"R Shiri","year":"2015","unstructured":"Shiri R et al (2015) The effect of excess body mass on the risk of carpal tunnel syndrome: a meta-analysis of 58 studies. Obes Rev 16(12):1094\u20131104","journal-title":"Obes Rev"},{"issue":"4","key":"14048_CR73","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000829","volume":"5","author":"AB Schmid","year":"2020","unstructured":"Schmid AB, Fundaun J, Tampin B (2020) Entrapment neuropathies: a contemporary approach to pathophysiology, clinical assessment, and management. Pain Rep 5(4):e829","journal-title":"Pain Rep"},{"issue":"11","key":"14048_CR74","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41366-025-01899-y","volume":"49","author":"M Rydberg","year":"2025","unstructured":"Rydberg M et al (2025) Body mass index and the risk of ulnar nerve entrapment in individuals without diabetes\u2014a longitudinal cohort study from Sweden: epidemiology and population health. Int J Obes 49(11):2358\u20132363","journal-title":"Int J Obes"},{"issue":"12","key":"14048_CR75","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00256-011-1177-4","volume":"40","author":"L Meylaerts","year":"2011","unstructured":"Meylaerts L et al (2011) Peroneal neuropathy after weight loss: a high-resolution ultrasonographic characterization of the common peroneal nerve. Skeletal Radiol 40(12):1557\u20131562","journal-title":"Skeletal Radiol"},{"key":"14048_CR76","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/103472","volume":"2012","author":"M Via","year":"2012","unstructured":"Via M (2012) The malnutrition of obesity: micronutrient deficiencies that promote diabetes. ISRN Endocrinol 2012:103472","journal-title":"ISRN Endocrinol"},{"key":"14048_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1566498","volume":"12","author":"B Johnson","year":"2025","unstructured":"Johnson B et al (2025) Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr 12:1566498","journal-title":"Front Nutr"},{"key":"14048_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100195","volume":"16","author":"BVB Johnson","year":"2025","unstructured":"Johnson BVB et al (2025) Diet quality and nutrient distribution while using glucagon-like-peptide-1 receptor agonist: a secondary cross-sectional analysis. Obes Pillars 16:100195","journal-title":"Obes Pillars"},{"issue":"1","key":"14048_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/cob.70070","volume":"16","author":"J Urbina","year":"2026","unstructured":"Urbina J et al (2026) Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: a narrative review. Clin Obes 16(1):e70070","journal-title":"Clin Obes"},{"issue":"100186","key":"14048_CR80","first-page":"2025","volume":"15","author":"W Butsch","year":"2025","unstructured":"Butsch W et al (2025) Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obes Pillars 15(100186):2025","journal-title":"Obes Pillars"},{"issue":"3","key":"14048_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2022-003300","volume":"11","author":"SC Bain","year":"2023","unstructured":"Bain SC et al (2023) Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study. BMJ Open Diabetes Res Care 11(3):e003300","journal-title":"BMJ Open Diabetes Res Care"},{"key":"14048_CR82","doi-asserted-by":"crossref","unstructured":"Salvatore M et al. (2025) Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes. medRxiv","DOI":"10.1101\/2025.06.03.25328908"},{"issue":"4","key":"14048_CR83","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ajcn\/9.4.414","volume":"9","author":"PM Dreyfus","year":"1961","unstructured":"Dreyfus PM, Victor M (1961) Effects of thiamine deficiency on the central nervous system. Am J Clin Nutr 9(4):414\u2013425","journal-title":"Am J Clin Nutr"},{"issue":"26","key":"14048_CR84","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJM198806303182604","volume":"318","author":"J Lindenbaum","year":"1988","unstructured":"Lindenbaum J et al (1988) Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 318(26):1720\u20131728","journal-title":"N Engl J Med"},{"issue":"1","key":"14048_CR85","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/jnnp-2022-329849","volume":"95","author":"C Kramarz","year":"2023","unstructured":"Kramarz C et al (2023) Nutritional peripheral neuropathies. J Neurol Neurosurg Psychiatry 95(1):61\u201372","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5(Peripheral Ne","key":"14048_CR86","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1212\/01.CON.0000455880.06675.5a","volume":"20","author":"NP Staff","year":"2014","unstructured":"Staff NP, Windebank AJ (2014) Peripheral neuropathy due to vitamin deficiency, toxins, and medications. Continuum (Minneap Minn) 20(5(Peripheral Nervous System Disorders)):1293\u20131306","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"14048_CR87","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1590\/S1980-57642008DN10400002","volume":"1","author":"ST Ferreira","year":"2007","unstructured":"Ferreira ST, Felice FG (2007) Neuroprotective actions of 2,4-dinitrophenol: friend or foe? Dement Neuropsychol 1(4):334\u2013338","journal-title":"Dement Neuropsychol"},{"key":"14048_CR88","doi-asserted-by":"publisher","first-page":"9426014","DOI":"10.1155\/2019\/9426014","volume":"2019","author":"MS Mohiuddin","year":"2019","unstructured":"Mohiuddin MS et al (2019) Glucagon-like peptide-1 receptor agonist protects dorsal root ganglion neurons against oxidative insult. J Diabetes Res 2019:9426014","journal-title":"J Diabetes Res"},{"issue":"2","key":"14048_CR89","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tem.2016.10.001","volume":"28","author":"G Muscogiuri","year":"2017","unstructured":"Muscogiuri G et al (2017) Glucagon-like peptide-1 and the central\/peripheral nervous system: crosstalk in diabetes. Trends Endocrinol Metab 28(2):88\u2013103","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"14048_CR90","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","volume":"33","author":"D Erbil","year":"2019","unstructured":"Erbil D et al (2019) GLP-1\u2019s role in neuroprotection: a systematic review. Brain Inj 33(6):734\u2013819","journal-title":"Brain Inj"},{"issue":"3","key":"14048_CR91","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00125-023-06072-6","volume":"67","author":"R Dhanapalaratnam","year":"2024","unstructured":"Dhanapalaratnam R et al (2024) Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia 67(3):561\u2013566","journal-title":"Diabetologia"},{"issue":"2","key":"14048_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.16242","volume":"169","author":"S Fan","year":"2025","unstructured":"Fan S et al (2025) Effect of the glucagon-like peptide-1 receptor agonists on diabetic peripheral neuropathy: a meta-analysis. J Neurochem 169(2):e16242","journal-title":"J Neurochem"},{"issue":"4","key":"14048_CR93","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa032782","volume":"352","author":"S Tesfaye","year":"2005","unstructured":"Tesfaye S et al (2005) Vascular risk factors and diabetic neuropathy. N Engl J Med 352(4):341\u2013350","journal-title":"N Engl J Med"},{"issue":"6","key":"14048_CR94","first-page":"717","volume":"10","author":"LM Hinder","year":"2017","unstructured":"Hinder LM et al (2017) Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome. Dis Model Mech 10(6):717\u2013725","journal-title":"Dis Model Mech"},{"issue":"12","key":"14048_CR95","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1016\/j.pain.2013.07.052","volume":"154","author":"AL Groover","year":"2013","unstructured":"Groover AL et al (2013) Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice. Pain 154(12):2658\u20132667","journal-title":"Pain"},{"issue":"7\u20139","key":"14048_CR96","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1089\/ars.2021.0278","volume":"37","author":"R Bonomo","year":"2022","unstructured":"Bonomo R, Kramer S, Aubert VM (2022) Obesity-associated neuropathy: recent preclinical studies and proposed mechanisms. Antioxid Redox Signal 37(7\u20139):597\u2013612","journal-title":"Antioxid Redox Signal"},{"issue":"12","key":"14048_CR97","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1002\/oby.23246","volume":"29","author":"BC Callaghan","year":"2021","unstructured":"Callaghan BC et al (2021) Dietary weight loss in people with severe obesity stabilizes neuropathy and improves symptomatology. Obesity (Silver Spring) 29(12):2108\u20132118","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"14048_CR98","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00125-017-4253-z","volume":"60","author":"Look AHEAD Research Group","year":"2017","unstructured":"Look AHEAD Research Group (2017) Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study. Diabetologia 60(6):980\u2013988","journal-title":"Diabetologia"},{"issue":"1","key":"14048_CR99","first-page":"108","volume":"11","author":"AP Rahayu","year":"2026","unstructured":"Rahayu AP et al (2026) Duration of diabetes mellitus (Dm) and obesity in patients with diabetic peripheral neuropathy (Dpn) type II diabetes mellitus. Cendekia Medika: Jurnal Stikes Al-Maarif Baturaja 11(1):108\u2013119","journal-title":"Cendekia Medika: Jurnal Stikes Al-Maarif Baturaja"},{"issue":"11","key":"14048_CR100","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s001250050586","volume":"39","author":"S Tesfaye","year":"1996","unstructured":"Tesfaye S et al (1996) Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia 39(11):1377\u20131384","journal-title":"Diabetologia"},{"issue":"3","key":"14048_CR101","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pcd.2014.07.006","volume":"9","author":"L Li","year":"2015","unstructured":"Li L et al (2015) Prevalence and risk factors of diabetic peripheral neuropathy in type 2 diabetes mellitus patients with overweight\/obese in Guangdong province, China. Prim Care Diabetes 9(3):191\u2013195","journal-title":"Prim Care Diabetes"},{"issue":"3","key":"14048_CR102","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.diabet.2008.11.004","volume":"35","author":"K Van Acker","year":"2009","unstructured":"Van Acker K et al (2009) Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 35(3):206\u2013213","journal-title":"Diabetes Metab"},{"issue":"5","key":"14048_CR103","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/mus.21802","volume":"42","author":"P Thaisetthawatkul","year":"2010","unstructured":"Thaisetthawatkul P et al (2010) Good nutritional control may prevent polyneuropathy after bariatric surgery. Muscle Nerve 42(5):709\u2013714","journal-title":"Muscle Nerve"},{"issue":"1","key":"14048_CR104","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/brain\/awu307","volume":"138","author":"CH Gibbons","year":"2015","unstructured":"Gibbons CH, Freeman R (2015) Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 138(1):43\u201352","journal-title":"Brain"},{"issue":"2","key":"14048_CR105","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.mcna.2018.10.013","volume":"103","author":"MP Bowley","year":"2019","unstructured":"Bowley MP, Doughty CT (2019) Entrapment neuropathies of the lower extremity. Med Clin North Am 103(2):371\u2013382","journal-title":"Med Clin North Am"},{"issue":"21","key":"14048_CR106","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1212\/01.wnl.0000262768.40174.33","volume":"68","author":"K Juhasz-Pocsine","year":"2007","unstructured":"Juhasz-Pocsine K et al (2007) Neurologic complications of gastric bypass surgery for morbid obesity. Neurology 68(21):1843\u20131850","journal-title":"Neurology"},{"issue":"2","key":"14048_CR107","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239\u2013245","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14048-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14048-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14048-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:02:29Z","timestamp":1786348949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-14048-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":107,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["14048"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14048-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"5 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"503"}}